Patient advocacy groups call for more use of HPV vaccine

18 October 2019
syringe_big

Patient advocacy groups HPV Action and the Teenage Cancer Trust have said that a new program in the UK, offering HPV vaccines for boys, is insufficient.

Allie Nawrat, pharmaceutical technology writer at industry analyst GlobalData, noted that, “unlike the existing program for girls, where the HPV vaccine is available for free until the age of 25, it will only be offered to boys aged 12 to 13.”

The groups are calling for older boys to be included in the immunization program, to help prevent cancer, which has been closely linked with HPV infection.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology